“LYNPARZA's new indication is a demonstration of AstraZeneca’s ongoing commitment to Australian women living with BRCA mutated ovarian cancer," said country president Liz Chatwin.

Latest Video
New Stories
-
Invites to medicines policy review working group
December 10, 2019 - - Latest News -
AusBiotech: Cuts threaten business sustainability
December 10, 2019 - - Latest News -
New report says 'Pelosi plan' would reduce US life expectancy
December 10, 2019 - - Latest News -
Sanofi acquires Synthorx ahead of strategy update
December 10, 2019 - - Latest News -
Current approach to HTA is the barrier to personalised medicine, not the health system
December 9, 2019 - - Latest News -
David Thomas: Matching the new world to an old system
December 9, 2019 - - Latest News -
'This is simply the way it has to be'
December 9, 2019 - - Latest News